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Abstract THRX-160209 is a potent antagonist at the M 2 muscarinic acetylcholine (ACh) receptor subtype which was designed using a multivalent strategy, simultaneously targeting the classical orthosteric site and a nearby site known to bind allosteric ligands. Here we describe three characteristics of THRX-160209 binding which are consistent with a multivalent interaction: (1) An apparent affinity of the multivalent ligand for the M 2 receptor subtype (apparent pK I = 9.51 + 0.22) which was several orders of magnitude greater than its two monovalent components (apparent pK I values < 6.0) (2) Specificity of THRX-160209 for the M 2 receptor subtype, as compared to the 

Introduction
The muscarinic receptor family consists of five subtypes that are found in smooth and cardiac muscle, epithelial and endothelial cells, secretory cells, neurons and inflammatory cells (Caulfield, 1993; Racke and Matthiesen, 2004) . These receptors represent attractive targets for drug design in a variety of therapeutic areas, including overactive bladder, chronic obstructive pulmonary disease and Parkinson's disease (Eglen et al., 2001; Katzenschlager et al., 2003; Barnes, 2004; Hegde et al., 2004) . However, most currently-marketed, muscarinic receptortargeted therapies exhibit significant side effects, some of which are due to potent drug interactions at undesirable muscarinic receptor subtypes outside the intended organ system. High sequence homology within the orthosteric site, across the five receptor subtypes, makes the synthesis of tissue-specific or subtype-specific drugs challenging (Hulme et al., 1990) . A drug with specificity for a given subtype or tissue is predicted to have increased efficacy but decreased side effects relative to a drug with equal affinity for all subtypes (Gainetdinov and Caron, 1999) .
Muscarinic receptors are known to be subject to modulation by ligands that do not bind to the ACh binding pocket (the "orthosteric site") (Ellis et al., 1991) . Targeting these 'secondary' or 'allosteric' sites may allow design of subtype-specific ligands, as these regions are less conserved than the orthosteric region among the muscarinic receptor subtypes. However, not all allosteric modulators of muscarinic receptors appear to bind to identical sites on the receptors (Trankle and Mohr, 1997; Birdsall et al., 2001) . Obidoxime is a valuable tool with which to define binding to the same region on M 2 receptors as the typical allosteric modulators gallamine and W84 (Ellis and Seidenberg, 1992; Trankle and Mohr, 1997) .
Based upon comparison with the X-ray crystal structure of bovine rhodopsin, the ACh binding pocket of the muscarinic M 2 receptor is believed to be located in a narrow cavity formed by the seven membrane spanning regions of the receptor (Wess, 1993; Wheatley et al., 1988) .
The typical 1 allosteric site is thought to be located on the extracellular lip of the receptor (Ellis et al., 1993; Leppik et al., 1994; Tucek and Proska, 1995) . Ligands such as gallamine and obidoxime have been shown to bind to this secondary binding site (Clark and Mitchelson, 1976; Trankle and Mohr, 1997 ) and this site is estimated to be in close proximity to the orthosteric site This article has not been copyedited and formatted. The final version may differ from this version.
Molecular Pharmacology Fast Forward. Published on May 3, 2007 as DOI: 10.1124 at ASPET Journals on May 1, 2017 molpharm.aspetjournals.org Downloaded from (Tucek and Proska, 1995) . Based upon this estimation, we believed that a priori design of novel multivalent ligands, designed to span and bind to both sites simultaneously, should be possible.
A multivalent approach to ligand design would be predicted to yield ligands with greater affinity and subtype specificity for one or more of the five muscarinic receptor subtypes among the family of receptors M 1 -M 5 . The valency of a ligand refers to the number of distinct binding interactions it makes with a target protein (Mammen et al., 1998a) . Multivalent binding by our definition is the simultaneous interaction of multiple binding motifs on a ligand with adjacent concavities on a target or adjacent targets. The principles of multivalency suggest that higher binding affinities can be achieved when multiple ligands are coupled and simultaneously bind to multiple sites on a single target (Mammen et al., 1998a; Mammen et al., 1998c) . The energetic basis of this phenomenon is that multivalent interactions allow the free energy gain of each component interaction between the multivalent ligand and its target but with reduced entropic cost relative to that of multiple separate (monovalent) ligands interacting with the same set of sites.
The source of this entropy savings is that translational freedom is given up by only a single rather than multiple molecules (Mammen et al., 1998b; Mammen et al., 1998c) . Therefore, the total free energy of interaction of multivalent ligands should be of greater magnitude than the sum of the free energies of interaction of the molecular components.
Furthermore, multivalent ligands have the potential to demonstrate greater target specificity than corresponding monovalent ligands if even one binding site interaction discriminates between related targets. Consequently, potent and selective muscarinic receptor ligands, developed using a multivalent approach, might prove to be valuable therapeutics. Others have used a similar strategy and have reported the advantages of a series of agonist-allostere bivalent ligands (Disingrini et al., 2006) . Here, we provide evidence for a multivalent interaction between the antagonist THRX-160209 and the muscarinic M 2 receptor. We suggest that this novel multivalent ligand simultaneously occupies the orthosteric site and the 'typical' allosteric site of the receptor resulting in tighter binding and greater subtype specificity than typically described with monovalent ligands.
This article has not been copyedited and formatted. The final version may differ from this version. fetal bovine serum and 250 µg/mL G-418 at 37°C under 5% CO 2 . Cells were grown to confluence and harvested with phosphate buffer saline containing 2 mM EDTA. Lifted cells were suspended in ice-cold 10 mM HEPES with 10 mM EDTA, pH 7.4 and homogenized using a cell disrupter. The homogenate was then sedimented by centrifugation (500 x g, 10 min). The supernatant was then centrifuged again (40,000 x g, 20 min) and the pellets were suspended in 10 mM HEPES buffer with 20 mM NaCl, pH 7.4 and stored at -80°C. (Cheng and Prusoff, 1973) .
To characterize the interaction between fragments of THRX-160209 when co-incubated in inhibition radioligand binding assays, fractional inhibition of [ 3 H]NMS binding data were analyzed according to methods adapted from the Loewe additivity model (Suhnel, 1998) .
Experimental data were normalized from CPM to fractional inhibition of [ pK I values for these terms. The apparent pK I for a multivalent ligand can be used for AB when calculating the multivalent effect, τ. This term is simply defined as τ = 1/i and more clearly demonstrates the degree of synergy when ligands are covalently linked.
For visualization of co-incubated fragment interactions, data were plotted according to the Bliss model of independence (Suhnel, 1998) . According to this model the fractional response of a This article has not been copyedited and formatted. The final version may differ from this version. were terminated as described above. In practice, these methods are similar to those described for our Inhibition Radioligand Binding studies, but the data are analyzed differently. CPM data were normalized to controls to yield percent of maximal specific binding. Data were fit to a kinetic allosteric ternary complex model as defined by Avlani et al (Avlani et al., 2004) to estimate the affinity for the free receptor and cooperativity with the radioligand. Equations were modified to fit our definitions of cooperativity, defined below. The equilibrium allosteric ternary complex model (Ehlert, 1988) is defined as: and is the midpoint of the occupancy curve for the radioligand in the presence of modulator, A.
However, because high concentrations of an allosteric ligand or entry blocker can delay the time required to reach equilibrium, a kinetic model is sometimes more appropriate.
Equation 4 is the standard equation for monoexponential association of an orthosteric ligand, A;
B LA denotes the specific binding of A in the presence of B, and t denotes time. The term k on,obs is the apparent association rate and is defined by the equation:
The term k off,obs is the observed dissociation rate of the orthosteric ligand in the presence of allosteric modulator and is defined by the equation:
Equation 6 is the equation for equilibrium binding of the orthosteric ligand in the presence of allosteric modulator, where K App is the parameter as defined in equation 3.
This article has not been copyedited and formatted. The final version may differ from this version. . When present with a test allosteric ligand, obidoxime induced rightward shifts of the concentrationresponse curves. These shifts were analyzed by nonlinear regression methods described by Lew and Angus (Lew and Angus, 1995) to check for competitive interactions. Fits to these models were compared using a partial F-test:
where pEC 50,diss is the concentration of allosteric modulator required to decelerate the dissociation rate of bound radioligand by 50% in the presence of obidoxime at a concentration, B. The constant -log C is the difference between the pK B of the antagonist (i.e. obidoxime) and the pEC 50,diss of the agonist, or in this case, the test allosteric modulator. Equation 8 is the equivalent This article has not been copyedited and formatted. The final version may differ from this version.
of a Schild plot with a slope of unity. Equation 9 is equivalent to a Schild plot with a slope ≠ 1.
Equation 10 is equivalent to a nonlinear Schild plot. Results were plotted in a manner analogous to Schild (Arunlakshana and Schild, 1959) for visualization purposes. occupied receptor) was determined by one-way ANOVA. Differences were considered to be statistically significant when P < 0.05
Results
Characterization of Ligand Affinities and Selectivities for Muscarinic Receptors Using Conventional Radioligand Inhibition Binding Assays
THRX-160209 is a novel molecule containing a benzhydryl (3-BHP) group linked to 4-aminopiperidine motif (4-ABP) by a C7 polymethylene chain (Figure 1 To demonstrate the multivalent nature of THRX-160209, various truncated analogues were prepared and tested alone, and in combination, in the M 2 inhibition radioligand binding assay. Fragments lacking the C7 alkyl chain (3-BHP and 4-ABP) bound with micromolar apparent affinities to the muscarinic receptors. The M 2 receptor apparent pK I 's were 5.39 ± 0.33 and 5.70 ± 0.03, respectively. Adding back the C7 alkyl chain gave the linker conjugated fragments, 3-BHP-L and 4-ABP-L. These compounds bound with an apparent affinity that was several orders of magnitude higher than the unmodified monomers, with M 2 receptor apparent pK I 's of 7.75 ± 0.07 and 8.28 ± 0.07, respectively (Table 1 ). The apparent affinity for the hydroxyl terminated linker analog (3-BHP-OH) was much lower with an apparent pK I of 6.73 ± 0.04. 
Excess Ligand Dissociation Assay to Determine Occupied Receptor Affinity for Allosteric Ligands
Kinetic assays using excess competing ligand were employed to study potential . The pEC 50,diss values for gallamine and W84 were determined to be 6.2 ± 0.12 and 7.2 ± 0.19, respectively. For THRX-160209, the pEC 50,diss was determined to be 6.5 ± 0.06, differing from the apparent pK I determined in inhibition binding studies by approximately three orders of magnitude. Similar to W84, a high concentration of THRX-160209 (100 µM) inhibited the dissociation rate of [ highest concentrations used (> 100 µM); these concentrations were similar to those required for dissociation rate retardation by the orthosteric ligands scopolamine (data not shown).
Excess Ligand Dissociation Assay -Interactions of Allosteric Ligands with Obidoxime
In excess ligand dissociation assays, obidoxime alone retards the dissociation rate of 4.15 ± 0.09 and 4.12 ± 0.14, respectively. These values were not significantly different from each other (one-way ANOVA, P > 0.05). According to the ATCM, these apparent pK B values should be equal to the high affinity pEC 50,diss value for obidoxime (pEC 50,diss = 4.1) determined in the absence of other allosteric modulators. Indeed, there were no significant differences between the obidoxime pEC 50diss and the apparent pK B values (one-way ANOVA, P > 0.05). These curve shifts were also transformed in a manner analogous to that described by Arunlakshana and Schild (Arunlakshana and Schild, 1959) to more easily visualize the data ( Figure 7B ).
Nonequilibrium Radioligand Binding Assay to Determine Cooperativity Factors and Affinity for the Unoccupied Receptor
This article has not been copyedited and formatted. The final version may differ from this version. Nonequilibrium radioligand binding assays were used to estimate the cooperativity factor (α) and affinity of allosteric modulators for the free M 2 receptor. The cooperativity factor describes the interaction of the allosteric modulator and the orthosteric ligand. It is defined as the ratio of affinity of a ligand for the free receptor compared to its affinity for the occupied receptor.
As defined in the allosteric ternary complex model (ATCM), α > 1 denotes negative cooperativity and α < 1 denotes positive cooperativity. Data for THRX-160209, W84 and gallamine using these experiments were fit to equations 2-7 (Lazareno and Birdsall, 1995; Christopoulos and Kenakin, 2002; Avlani et al., 2004) . Figure 8 shows the nonequilibrium concentration-response curves for each compound tested. The curves for W84 and gallamine were biphasic, as would be predicted by the ATCM. The cooperativity factors determined for gallamine and W84 were 45 ± 9.14 (pα = 1.7) and 6.9 ± 1.35 (pα = 0.83), respectively, while the pK A 's (affinity for the freereceptor) were 8.2 ± 0.05 and 8.0 ± 0.07, respectively. For THRX-160209, the curves were monophasic and yielded a cooperativity factor of 2547 ± 281 (pα = -3.4) and a pK A of 10.2 ± 0.14.
The ratio of the free and [ 3 H]NMS-occupied receptor affinities also provided an estimate of the cooperativity factor. For all compounds tested, the estimated cooperativity factors (pEC 50,diss -pK A ) are in good agreement with the experimentally determined cooperativity factor (e.g. THRX-160209 estimated pα = -3.7, experimental pα = -3.4; Table 2 ), thus these data are in good agreement with the affinity estimates for the occupied receptor as predicted by the ATCM.
However, as these values follow the rules of an allosteric interaction, the cooperativity factor for THRX-160209 does not seem practical. A cooperativity factor of this magnitude is indicative of a competitive rather than allosteric interaction. Other concerns regarding the validity of these analysis methods were described recently. May and colleagues reported that the assumptions of the ATCM may not hold for a multivalent ligand (May et al., 2007) . However, as they suggest, we believe that deviation from the model would only be significant for a multivalent ligand with positive cooperativity rather than one with negative cooperativity.
This article has not been copyedited and formatted. The final version may differ from this version. , respectively) ( Figure 9C ). These results are consistent with a multivalent interaction (Kramer and Karpen, 1998; Rao et al., 1998; Smith et al., 2006) . Similarly, the presence of orthosteric or allosteric muscarinic ligands accelerated the rate of dissociation of , t ½ = 0.93 ± 0.13 min), respectively. These rates are comparable to the rate observed in the presence of the antagonist atropine.
Discussion
This article has not been copyedited and formatted. The final version may differ from this version. The binding interaction of THRX-160209 to muscarinic receptors exhibits three characteristics which are typical of multivalent systems. The first of these typical characteristics is high affinity. High affinity of THRX-160209 is the result of fusing two ligands into a single multivalent ligand. Unconnected, these monovalent ligands have low (micromolar) apparent affinities for the muscarinic receptors; when connected together with a seven carbon chain, the affinities toward the M 2 muscarinic receptor subtype were increased by three to four orders of magnitude. Data for the seven carbon chain fragments, 3-BHP-L and 4-ABP-L, described here suggest that the linker itself might play a significant role in receptor binding. However, estimating the linker contribution to THRX-160209 affinity, based on these affinity increases, is problematic.
Given that the seven carbon linker is hydrophobic, it is plausible that this portion of the molecule might bind to hydrophobic regions in the interior of the protein as opposed to interacting with residues on the surface. Such a phenomenon would likely lead to an overestimation of the contribution of the seven carbon linker to the overall affinity of THRX-160209 since the polar functionality found in the intact multivalent ligand, THRX-160209, would likely preclude such a binding mode. Indeed, some evidence in support of this hypothesis can be seen in the comparison with 3-BHP-OH which displays a terminal polar hydroxyl group. Interestingly, this change leads to a 10.5-fold reduction in apparent binding affinity relative to the methyl terminated linker conjugate, 3-BHP-L. To summarize, the actual contribution of the linker to the binding of the multivalent compound remains unknown at this time, but we anticipate it to be less than is suggested by the binding of these linker analogs.
Co-incubating THRX-160209 fragments, such as 4-ABP-L with 3-BHP, resulted in only a small increase in apparent M 2 affinity, as predicted by an additive model of ligand affinity enhancement. In contrast, the increase in affinity of THRX-160209 relative to the co-incubated ligands demonstrates the synergy possible when ligands are covalently linked. The gains in affinity exhibited by the intact ligand over the fragments are consistent with a multivalent ligand (Mammen et al., 1998a) .
A second feature of some multivalent systems is specificity. The challenge in discovering ligands with specificity for a given muscarinic receptor subtype or group of subtypes is due in part receptors (Bonner et al., 1988) . Because the muscarinic ACh receptor primary binding site is thought to be highly conserved across all subtypes, these selectivity ratios suggest that THRX-160209 binds, at least in part, to a region outside of the primary binding pocket.
Consistent with this proposal is the observation that THRX-160209 stabilizes the [ From mutagenesis studies, amino acid residues essential for binding the wellcharacterized allosteric modulators gallamine and W84 include the M 2 -EDGE sequence, M 2 -Tyr 177 and M 2 -Thr 423 (Leppik et al., 1994; Voigtlander et al., 2003) . Of these, only M 2 -D 173 and M 2 -Y 177 can be found in other subtypes (Bonner et al., 1988) . The present study has not examined binding of THRX-160209 to appropriate mutant M 2 receptors to confirm interactions with these specific amino acids; however we have shown a competitive interaction between obidoxime and THRX-160209. Obidoxime and THRX-160209 apparently bind to an overlapping region coincident with other typical muscarinic allosteric agents, such as W84 and gallamine.
The M 2 receptor specificity of THRX-160209 is therefore likely the result of the interaction with this secondary site.
A third feature of some multivalent systems is fragment-induced acceleration of dissociation rates. As described above, dissociation kinetics of radiolabeled ligands are often determined following the addition of excess, unlabeled competing ligand, to prevent re-association with the receptor. To investigate the multivalent mode of binding of THRX-160209, an "infinite" dilution protocol was employed. In these "infinite" dilution studies, dilution of the assay mixture reduces the radioligand concentration such that minimal radioligand re-association This article has not been copyedited and formatted. The final version may differ from this version. occurs. Typically, estimates of ligand dissociation rates should be independent of whether determined with the excess competing ligand assay or the "infinite" dilution assay. However, this is not necessarily true for multivalent ligands and differences in dissociation rate would be expected if a competing monovalent ligand alters the affinity of the multivalent ligand for the receptor. Certain systems allow the entry and binding of a fragment to a binding pocket with a partially bound multivalent ligand -this is typical of some, but not necessarily all, multivalent systems (Rao et al., 1998; Smith et al., 2006) . From our data, it appears that fragment-induced acceleration is a feature of the THRX-160209 interaction with the M 2 receptor. This acceleration is of particular interest since this phenomenon distinguishes multivalent from monovalent systems (Rao et al., 1998; Smith et al., 2006) . Interestingly, using the "infinite" dilution protocol, In contrast, the actions of the 3-BHP portion were more similar to those of an orthosteric ligand, suggesting this region of THRX-160209 binds to the orthosteric site.
In conclusion THRX-160209 is an example of a multivalent ligand that simultaneously occupies two distinct sites on a G-protein coupled receptor, specifically the orthosteric site and typical allosteric site of the muscarinic M 2 receptor. This rationally designed multivalent ligand competitively inhibits receptor activation at the ACh binding pocket with marked subtype specificity as a result of interaction with a low subtype homology secondary site. The high affinity displayed by THRX-160209 is likely the result of a relatively slow, step-wise dissociation of two tethered pharmacophores (Figure 10 ). These results demonstrate that multivalent ligand design can lead to enhanced affinity and target specificity. THRX-160209 illustrates the potential of the multivalent approach to provide high affinity ligands can discriminate between highly homologous proteins.
This article has not been copyedited and formatted. The final version may differ from this version. We refer to the typical allosteric site as the secondary binding site that binds most described muscarinic allosteric ligands, including gallamine, W84 and obidoxime.
2 Concentration-effect curves were best fit using a four-parameter logistic function, except for obidoxime where a two-site fit was used. The upper plateau was the k off and set at 100%. When checking for competitive interactions with obidoxime, the k off,obs , determined in the absence of test allosteric modulator and presence of obidoxime was the upper plateau, again set at 100%. The lower plateau was fixed at 0%. Hill coefficients were fixed at 1, as they did not differ significantly from unity. The midpoint of the curve is the EC 50,diss , or the concentration of allosteric modulator required to decelerate the dissociation rate of bound radioligand by 50% and is the affinity of the allosteric ligand for the receptor when orthosteric radioligand is bound.
This article has not been copyedited and formatted. The final version may differ from this version. were normalized to dissociation rates determined in the absence of test allosteric modulator to account for the effects of obidoxime. Data are mean ± standard error values from three independent experiments and were fit to a four-parameter logistic equation. Fig. 7 . Analysis of obidoxime-induced shifts in concentration-effect curves for THRX-160209 ( ), W84 ( ) and gallamine ( ). A, Obidoxime-induced curve shifts were analyzed using nonlinear regression (Lew and Angus, 1995) , fitting best to eq. 8. B, Curve shifts were expressed as dose ratios (DR) in the form of a Schild plot. Dose ratios were calculated by dividing the EC 50,diss determined in the presence of obidoxime by the EC 50,diss determined in the absence of obidoxime. This article has not been copyedited and formatted. The final version may differ from this version. determined using excess ligand dissociation assays; pK A : negative log value of the equilibrium dissociation constant for test compounds binding to unoccupied receptors determined from nonequilibrium radioligand binding assays; pα: negative log value of the cooperativity factor (α) determined from nonequilibrium radioligand binding assays.
